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INTRODUCTION
The antiphospholipid syndrome (APS) is characterized by 
the presence of antiphospholipid antibodies associated with 
arterial thrombosis, venous and/or microangiopathic, recurrent 
gestational morbidity and/or thrombocytopenia. It can be 
primary or secondary to other autoimmune diseases, mainly 
to systemic lupus erythematosus (SLE), to chronic infectious 
diseases or to neoplasias.1,2 
Antiphospholipid antibodies are autoantibodies whose 
targets are cellular membrane phospholipids and/or proteins 
combined with phospholipids, like beta-2 glycoprotein I (β2-
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ABSTRACT 
Objective: To evaluate the prevalence of lupus anticoagulant (LAC) and isotypes of anticardiolipin (ACL) antibodies 
and its possible clinical associations. Patients and methods: A retrospective study analyzed clinical and laboratorial 
manifestations in individuals who showed positive antiphospholipid antibodies followed-up at Hospital Edmundo 
Vasconcelos from March 2005 to June 2006. Results: 106 participants (mean age of 42.2 ± 14.1 years at inclusion and 
female gender in 84% of patients) were included in the study. The prevalence of thrombosis was 17.9% (19/106 patients) 
and pregnancy morbidity was 12.3% (13/106 patients). The antiphospholipid syndrome (APS) was confirmed in 23.6% 
(25/106 patients), and it was primary in 68% (17/25 patients) and secondary in 32% (8/25 patients). The ACL antibodies 
were found in 97.1% (103/106) and LAC in 11.4% (5/44 of the serum samples tested). IgM, IgG and IgA ACL isotypes 
were respectively found in 100%, 23.3% and in 4.9% of these ACL positive sera. For APS diagnosis the sensitivity of 
IgM ACL was 92% and its specificity was 1.2%, while IgG ACL had a sensitivity of 40% and specificity of 82.5%. 
The absence of IgG ACL had a high negative predictive value for APS diagnosis (81.4%).The analysis of the Receiver 
Operating Characteristic (ROC) curve showed larger area under the curve for ACL IgG and LAC. Conclusion: In a 
random sample of individuals with positive antiphospholipid antibodies, IgG ACL and LAC showed a larger specificity 
for APS diagnosis which had been characterized by a higher prevalence of thrombosis.
Keywords: antiphospholipid syndrome, anticardiolipin antibodies, lupus anticoagulant, thrombosis, fetal loss.
GPI) and prothrombin. The main antiphospholipid antibodies 
are the lupus anticoagulant (LAC), and anticardiolipin (ACL), 
which can be IgG, IgM or IgA.2 The presence of LAC or 
high titers of ACL is an important independent risk factor for 
thrombosis.3 Furthermore, these autoantibodies also help in 
the diagnosis of APS, composing the classification criteria 
for this entity.4,5
In this study we attempted to evaluate the prevalence 
of clinical manifestations associated with the presence of 
antiphospholipid antibodies, to compare the prevalence of 
these manifestations and different antiphospholipid antibodies 
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in patients with and without APS and to verify the performance 
of different tests to confirm the syndrome.
PATIENTS AND METHODS
A retrospective study was performed through active search of 
positive tests results for ACL and LAC in the clinical analyses 
laboratory at Hospital Professor Edmundo Vasconcelos, 
from March 2005 to June 2006. Later, the medical records 
of these individuals were analyzed. A hundred and six 
patients were included according to the following criterion: 
presence of ACL superior to 10 MPL, APL and/or GPL and/
or positivity of LAC. The patients with antiphospholipid 
antibodies were divided into two groups: those who fulfilled 
the Sapporo Classification Criteria for APS4 and those who 
did not fulfill these criteria. The groups were compared 
regarding clinical manifestations, and the contribution of 
each antiphospholipid antibody to the diagnosis of APS was 
statistically evaluated. 
The search of ACL was performed by enzyme immunoassay 
(ELISA) with the participant’s serum using INOVA 
Diagnostics’ kits. The results were issued in MPL, APL and 
GPL units for IgM, IgA and IgG, respectively. The LAC test 
was performed with the subjects’ plasma with the following 
tests: activated partial thromboplastin time (APTT) and 
dilute Russell’s viper venom time (dRVVT), according to 
international guidelines.6
The study was approved by the Hospital Professor 
Edmundo Vasconcelos ethics commission. 
STATISTICAL ANALySIS 
The chi square or Fisher tests were employed to analyze 
categorical variables, while the Student's t or Mann-Whitney’s 
tests were used to compare the numeric variables. The kurtosis 
and skewness coefficients were calculated to verify if the 
numeric variables presented normal distribution. Values of P 
inferior to 0.05 were considered significant.
The correlation among the ACL IgM, IgA and IgG 
levels and with the presence of LAC was performed by the 
Spearman’s rank correlation coefficient. For each diagnosis 
test, sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) were calculated, besides the 
construction of the ROC (Receiver Operating Characteristic) 
curve with the area below the curve and confidence interval 
of 95% (CI 95%). The gold standard used for the diagnosis of 
APS was the Sapporo Classification Criteria.
The risk of thrombosis associated with each test diagnosis 
of the study was done by logistic regression, stepwise. The 
results were expressed in odds ratio with confidence interval 
(CI) of 95%. 
RESULTS
Positive tests for antiphospholipid antibodies were found 
in 106 individuals. The participants of the study had mean 
age of 42.2 years with standard deviation (SD) of 14.1 years 
in the age range between 10 and 80 years, and most were 
female (84%).
Episodes of thrombosis were diagnosed in 17.9% (19/106) 
of the patients. Venous thrombosis was present in 73.7% 
(14/19) and arterial thrombosis in 31.6% (6/19). Gestational 
morbidity was observed in 12.3% (13/106) of the patients. The 
Sapporo Classification Criteria for APS were fulfilled in 23.6% 
of the cases (25/106 patients). Among them 68% presented the 
primary form and 32%, the secondary form of the disease – six 
of them with SLE diagnosis, one with chronic hepatitis C, and 
one with chronic infection by HIV.
ACL prevalence was 97.1% (103/106 patients) and LAC 
was 11.4% (5/44 of the patients evaluated). ACL IgM, IgG and 
IgA were respectively found in 100%, 23.3% and 4.9% of the 
ACL positive sera (Table 1). ACL IgM, IgG and IgA had mean 
titers of 35.5 MPL, 32.9 GPL and 19.1 APL, respectively.
Patients with and without APS presented similar data 
regarding age (45.2 ± 13.1 versus 41.2 ± 14.3 years, P = 0.198) 
for the female gender (84% versus 83.9%, P = 0.995) and 
for ACL IgM (92% versus 98.7%, P = 0.075) and ACL IgA 
(4% versus 4.9%, P = 0.889) frequencies. Nevertheless, the 
prevalence (40% versus 17.2%, P = 0.019) and mean levels 
of ACL IgG (38.8 ± 21.8 GPL versus 28.7 ± 28.7 GPL, P = 
0.038) were higher in patients with APS compared with those 
without APS. A significant large number of individuals with 
mean levels of ACL IgG above 40 GPL was also observed 
among patients with APS compared with those without APS 
(16% versus 2.5%, P = 0.001). As for ACL of IgM class, 
there was no significant difference between the groups with 
and without APS regarding the number of individuals with 
mean levels superior to 40 MPL (24% versus 13.6%, P = 
0.215) (Table 1). 
Of the 44 patients in the LAC search, five had a positive test 
(11.3%) – three with diagnosis of APS according to the Sapporo 
Classification Criteria, P = 0.336. Patients with APS presented 
a higher frequency of ACL IgM and IgG concomitant (40% 
versus 17.2%, P = 0.018) compared with those without APS. 
Patients with APS presented a greater prevalence of arterial 
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thrombosis (20% versus 1.2%, P < 0.001), venous thrombosis 
(44% versus 3.7%, P < 0.001) and gestational morbidity (48% 
versus 1.2%, P < 0.001) compared with individuals who 
presented antiphospholipid antibodies without fulfilling the 
classification criteria for APS (Table 1).
In a multivariated analysis, the antiphospholipid antibodies 
LAC and ACL (IgM, IgA, and IgG) did not seem significantly 
associated to a greater risk of thrombosis. ACL IgG presented 
a risk of 2.4 times for thrombosis, but the CI 95% from 0.4 to 
13.7 was not significant (P = 0.315). 
The sensitivity of ACL IgM was 92%, and its specificity 
was 1.2% for the diagnosis of APS. PPV was 22.3% and NPV 
was 33.3% for ACL IgM. The ROC curve demonstrated an area 
under the curve of 0.466 with CI 95% of 0.332-0.600 (Figure 
1). The sensitivity of ACL IgG was 40%, and its specificity 
was 82.5% for the diagnosis of APS. The PPV for ACL IgG 
was 41.6% and NPV, 81.4%. The ROC curve demonstrated 
an area under the curve of 0.613 with CI 95% of 0.479-0.746 
(Figure 2). The sensitivity of LAC was 12%, and its specificity 
was 97.5% for the diagnosis of APS. PPV was 60% and NPV 
was 78.2%. The ROC curve demonstrated an area under the 
curve of 0.558 with CI 95% of 0.376-0.740 (Figure 3). The very 
low prevalence of ACL IgA did not allow a similar analysis 
regarding the performance of this diagnostic test.
DISCUSSION
In this study, all ACL IgM, IgG and IgA tests were researched, 
besides LAC tests performed in the general hospital laboratory 
for 16 months. The obtained results of the antiphospholipid 
antibodies research were confronted with the clinical 
manifestations and personal antecedents presented by the 
participants of the study and with the Sapporo classification 
criteria for APS.4 ACL of IgG class and LAC were the most 
specific tests for the diagnosis of APS, while ACL of IgM 
class was too sensitive and little specific. Patients with APS 
diagnosis presented higher titers of ACL class IgG. However, 
the retrospective design of the present study prevents causality 
conclusions.
The standardization of diagnostic tests for antiphospholipid 
antibodies research has been a challenge, since diverse studies 
demonstrated a great variability of the results obtained with 
different commercial kits and in-house techniques of ELISA 
among laboratories for the ACL research.7-10 In this regard, it 
would be interesting to extend our findings using commercial 
kits for the detection of ACL of different origins. Also for the 
LAC search, heterogeneity of results is observed in different 
laboratories and used techniques.11-14 International consensuses 
for standardization the antiphospholipid antibodies research 
have been performed to improve interlaboratorial agreement. 
Table 1
Demographic, laboratorial and clinical data of antiphospholipid positive patients with and without APS
Variables APS (n = 25) Absence of APS (n = 81) P
Age, years 45.2 ( ± 13.1) 41.2 ( ± 14.3) 0.198
Female 21 (84%) 68 (83.9%) 0.995
LAC§ (n = 44) 3/16 (18.8%) 2/28 (7.1%) 0.336
ACL IgM 23 (92%) 80 (98.7%) 0.075
ACL IgA 1 (4%) 4 (4.9%) 0.889
ACL IgG 10 (40%) 14 (17.2%) 0.019*
ACL IgM e IgG 10 (40%) 14 (17.2%) 0.018*
ACL IgM > 10MPL 43.6 ( ± 49.0) 33.1 ( ± 35.0) 0.382
ACL IgM > 40MPL 6 (24%) 11 (13.6%) 0.215
ACL IgA > 10 APL 14.3 (NA) 20.3 ( ± 7.5) 0.480
ACL IgG > 10GPL 38.8 ( ± 21.8) 28.7 ( ± 28.7) 0.038*
ACL IgG > 40GPL 4 (16%) 2 (2.5%) 0.010*
Thrombosis 15 (60%) 4 (4.9%)  < 0.001*
 Venous 11 (44%) 3 (3.7%)  < 0.001*
 Arterial 5 (20%) 1 (1.2%)  < 0.001*
Gestational morbidity 12 (48%) 1 (1.2%)  < 0.001*
NA = non appliable; ACL = anticardiolipin; LAC = lupus anticoagulant. § The LAC test was performed in 44 of the patients included in the study. *Significant statistic difference.
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The detection of ACL by a commercial kit in the present study 
showed high prevalence of ACL IgM in low titers in individuals 
without the diagnosis of APS, suggesting its high sensitivity 
for ACL IgM. However, the literature demonstrates that there 
is a tendency to the association of false positive results and 
low titers of ACL IgM, mainly in individuals with rheumatoid 
factor or cryoglobulins.18-19
The discovery of high specificity and a larger area under 
the ROC curve for the diagnosis of APS with LAC positivity 
in our study is in agreement with previously reported data.3 The 
presence of LAC is the main risk factor for gestational morbidity 
in APS and for thrombotic events, despite the vascular bed or 
type of thrombosis, the presence of SLE and the method used to 
find it.3 In this study, the finding of LAC positivity (12%) was 
inferior to the one observed in the literature (50-55%).1,23-25 This 
finding can be underestimated since its research was performed 
in only 44 of the 106 participants. Maybe a minor knowledge 
about the importance of LAC as a risk factor for thrombosis 
and its importance for the diagnosis of APS has contributed 
for its minor solicitation.
 In our study, the presence of ACL class IgG also presented 
a high specificity for the diagnosis of APS, in agreement with 
the literature.3 The presence of moderate to high titers of ACL 
class IgG is a risk factor for thrombosis, but with less intensity 
in relation to LAC.3 The great number of individuals without 
APS and with ACL in low titers observed in the present study 
is probably due to a low cut off for ACL positivity (10 units 
GPL, MPL, or APL) oriented by the kit’s manufacturer. As it 
would be expected, most individuals without APS presented 
ACL IgM in low titers. Nevertheless, the difference between 
the groups was not significant regarding the mean of MPL units, 
because a few individuals without APS presented elevated 
titers of ACL class IgM. In the Sapporo classification criteria, 
the cut off used to define the ACL positivity was 20 GPL or 
MPL units.4 Recently, with the objective of obtaining a higher 
specificity in the diagnosis of APS, the Sapporo criteria were 
updated and the cut off was raised to 40 GPL or MPL units, 
or levels above the 99 percentage.5 The high prevalence of 
antiphospholipid antibodies in individuals without APS is also 
due to the fact that these tests were requested for patients with 
some clinical suspicion. The prevalence of antiphospholipid 
antibodies varies from 1.0 to 5.6% in the general population 
without suspicion of APS clinical scenario and tends to increase 
with aging, mainly in individuals with comorbidities.20 
 ACL class IgA was only detected in four individuals 
and among them only one patient had APS. Due to the low 
prevalence of this autoantibody, it was not possible to analyze it 
separately. This isotype does not seem to increase the sensitivity 
for the diagnosis of APS.5 It just helps to identify subgroups of 
patients and it is highly prevalent in african-american patients 
with SLE and correlating with thrombocytopenia, cutaneous 
ulcers and vasculitis.21,22 
 The patients with diagnosis of APS evaluated in this 
study presented similar data to those in most studies in the 
literature regarding the frequency of the female gender and the 
prevalence of venous and arterial thrombosis, and of obstetrical 
morbidity.1,23-25
As for antiphospholipid antibodies in patients with the 
diagnosis of APS, the prevalence of ACL class IgM was 92%, 
superior than the 76.4 to 77% described in other studies23,24 and 
far above the 39.4% described in a study performed by the same 
author using the in-house ELISA technique,25 which confirms 
the high sensitivity of ACL IgM of the tested kit. Although ACL 
IgG was more specific for the diagnosis of APS in this study, 
Figure 1. ROC curve for ACL IgM. Figure 2. ROC curve for ACL IgG. Figure 3. ROC curve for LAC.
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its prevalence of 40% was inferior to what was previously 
described in patients with APS (75.7-81.6%).23-25
 In conclusion, our data reveal the importance of the 
positivity of LAC and ACL class IgG in the diagnosis of APS 
in individuals cared for in a general hospital. Besides that, the 
present study shows that ACL antibodies of the IgM isotype, 
despite its high prevalence, does not seem to contribute in 
helping the syndrome diagnosis, as well as the IgA isotype.
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